Sawai Pharmaceutical Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 17, 2027The maintenance fee for Preparation containing saxagliptin and method for producing the same (US 11,786,472) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Orally disintegrating tablet coated with film (US 11,826,473) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Orally disintegrating tablet coated with film (US 10,588,856) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Oral cavity disintegrating tablet and method of producing the same (US 9,314,454) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,314,454 | Oral cavity disintegrating tablet and method of producing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,399,064 | Pitavastatin-containing preparation and method for producing same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,588,856 | Orally disintegrating tablet coated with film In force · From the USPTO record | In force | From the USPTO record | |
| US 10,925,861 | Mirabegron-containing tablet, method for producing mirabegron-containing pharmaceutical preparation, and method for producing mirabegron-containing granulated product In force · From the USPTO record | In force | From the USPTO record | |
| US 11,167,031 | Additive composition for orally disintegrating tablet In force · From the USPTO record | In force | From the USPTO record | |
| US 11,173,122 | Additive composition for orally disintegrating tablet In force · From the USPTO record | In force | From the USPTO record | |
| US 10,890,572 | Mouthfeel evaluation method and mouthfeel evaluation apparatus for orally disintegrating test object In force · From the USPTO record | In force | From the USPTO record | |
| US 10,989,647 | Orally disintegrating tablet evaluating method, and orally disintegrating tablet evaluating device In force · From the USPTO record | In force | From the USPTO record | |
| US 11,826,473 | Orally disintegrating tablet coated with film In force · From the USPTO record | In force | From the USPTO record | |
| US 11,786,472 | Preparation containing saxagliptin and method for producing the same In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 4 lapsed for an unpaid fee · 11 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 1 abandoned · 10 no status recorded